Medicare open enrollment has commenced and will remain open until December 7. This window allows participants to modify their plans before changes take effect on January 1, amid significant shifts to Part D and Social Security payments.
The 3.6% COLA and the $75 Monthly Social Security Bump
The current enrollment period arrives as the Social Security Administration announced a 3.6% cost-of-living adjustment (COLA) starting in 2027. According to the report,this increase provides an additional $75 per month for nearly 72 million Social Security beneficiaries and approximately 7.3 million Supplemental Security Income recipients.
This adjustment is part of a broader struggle against inflation that continues to squeeze senior budgets. With midterm elections approaching, the cost of living has become a primary concern for voters, making the timing of these healthcare and income adjustments politically sensitive.
Rising Costs: The $2,400 Part D Cap and $700 Deductible
Significant financial shifts are hitting Medicare Part D in 2027. The report states that the annual out-of-pocket expense cap for Part D drugs will climb to $2,400, an increase from the $2,100 cap in place for 2026. Simultaneously, the standard deductible is set to rise from $615 to $700.
Adding to these costs is the conclusion of a temporary Part D premium subsidy. This program, originally implemented by the Joe Biden administration in 2024 as a response to the 2022 Inflation Reduction Act, is being ended by the Trump administration. While the Centers for Medicare & Medicaid Services (CMS) projects only modest price inceases for the average person, the removal of this subsidy may create new financial pressures for vulnerable enrollees.
Saving $685 Million via Negotiated Prices for 15 Drugs
To offset rising costs, the government is implementing negotiated prices for 15 specific drugs under a Biden-era law. This includes high-demand medications for diabetes and weight loss, specifically Ozempic, Rybelsus, and Wegovy. The Centers for Medicare & Medicaid Services (CMS) expects these negotiations to reduce prescription drug costs for enrollees by $685 million in 2027.
Furthermore, starting January 1, Medicare will expand coverage to include a wide array of medications. These include Trelegy Ellipta, Xtandi, Pomalyst, Ibrance, Ofev, Linzess, Calquence, Austedo/Austedo XR, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet/Janumet XR, and Otezla.
The $90 Trump Rebate and the 35 Million Excluded Advantage Users
President Donald Trump has introduced targeted financial relief to coincide with these changes. As reported by the source, the administration will issue one-time payments of $90 in October to more than 20 million Medicare enrollees to assist with Part B premiums, a move costing roughly $2 billion. Additionally, about 1 million individuals will receive $500 rebate checks for Affordable Care Act premiums.
However, this relief is not universal. Roughly 35 million Medicare Advantage enrollees, along with millions of low-income recipients and people with disabilities, are ineligible for the $90 rebate. Eligible beneficiaries will receive their funds via direct deposit or a Treasury Department paper check later this month.
David Lipschutz's Warning on Medicare Advantage Benefit Scaling
Despite the projected savings from CMS, David Lipschutz, co-director of the Center for Medicare Advocacy,warns of significant disruptions. Lipschutz notes that some Medicare Advantage plans are scaling back benefits—specifically dental coverage—and increasing cost-sharing, while some providers are exiting specific geographic areas entirely.
A critical gap in the current reporting is the lack of official government commentary on these disruptions; the report notes that CMS did not respond to an Associated Press request for comment. It remains unclear exactly which geographic regions will see the most significant plan withdrawals or how many enrollees will be forced to switch plans due to these business decisions.
Comments 0